Physician profile
Tammy Milbocker
NPI 1790209161
$3,268.24
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $689 · 2023: $2,158 · 2024: $422.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,337 · Education: $242.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,337.46 |
| Education | $242.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,259.19 | 2022-2024 | Tezspire, Fasenra, Breztri |
| Glaxosmithkline, LLC. | $401.72 | 2022-2024 | Nucala, Trelegy Ellipta, Arexvy |
| Jazz Pharmaceuticals INC. | $309.20 | 2022-2024 | |
| Mylan Specialty L.P. | $265.17 | 2022-2024 | Yupelri |
| Regeneron Healthcare Solutions, INC. | $226.35 | 2023-2024 | Dupixent |
| Boehringer Ingelheim Pharmaceuticals, INC. | $201.57 | 2022-2024 | Ofev, Stiolto Respimat, Spiriva Respimat |
| Actelion Pharmaceuticals US, INC. | $179.86 | 2022-2023 | Opsumit, Uptravi |
| Amgen INC. | $91.71 | 2022-2024 | Tezspire |
| Grifols USA, LLC | $72.74 | 2022-2024 | Prolastin-C Liquid |
| Genzyme Corporation | $67.40 | 2022-2023 | |
| Electromed, INC. | $45.72 | 2023 | Smartvest |
| Axsome Therapeutics, INC. | $37.90 | 2023 | Sunosi |
| Abbvie INC. | $20.63 | 2022 | |
| Inspire Medical Systems, INC. | $16.57 | 2023 | Inspire |
| Pulmonx Corporation | $16.31 | 2024 | Zephyr Endobronchial Valve, Pulmonx Chartis Tablet Console, Chartis Catheter |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $15.48 | 2024 | Rexulti |
| Insmed, INC. | $14.64 | 2022 | |
| Dexcom, INC. | $13.30 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $12.78 | 2023 | Gammagard |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tammy Milbocker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.